Last updated on June 2018

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

Brief description of study

The purpose of this study is to evaluate the safety and efficacy of single and repeated intravitreal injections of GB-102 in subjects with neovascular (wet) age-related macular degeneration.

Detailed Study Description

In this 2-part study, Part 1 is a multicenter, open-label, safety, tolerability, and systemic exposure evaluation to Sunitinib in escalating doses of a single IVT injection of GB-102, while Part 2 is a multicenter, double-masked, randomized (1:1:1), parallelgroup, safety, and efficacy evaluation of repeated IVT injections of 2 dose levels of GB102 compared with aflibercept.

Clinical Study Identifier: NCT03249740

Contact Investigators or Research Sites near you

Start Over

Elisa Martinez

Retinal Consultants of Arizona
Gilbert, AZ United States
  Connect »

Valentina Bozikovic

Retina Institute of California
Arcadia, CA United States
  Connect »

Janet Kurokouch

Retina-Vitreous Associates Medical Group
Beverly Hills, CA United States
  Connect »

Cari Novak

Midwest Eye Institute
Indianapolis, IN United States
  Connect »

Courtney Wheeler

Retina Research Institute of Texas
Abilene, TX United States
  Connect »

Michelle Curry

Texas Retina Associates
Arlington, TX United States
  Connect »

VP, Global Clinical Development Operations

Retina Macula Specialists of Miami, LLC
Miami, FL United States
  Connect »

Isabel Lezcano

Ophthalmic Consultants of Long Island
Lynbrook, NY United States
  Connect »

Ivana Gunderson

Retina Research Center, PLLC
Austin, TX United States
  Connect »

Beatrice Guajardo

Medical Center Ophthalmology Associates
San Antonio, TX United States
  Connect »